Edesa Biotech, Inc. announced the pricing of an underwritten public offering expected to generate approximately $25.0 million in gross proceeds. The company plans to use the estimated net proceeds of $23.1 million for general corporate purposes, including working capital, capital expenditures, and research and development expenses.
Key Details
- Offering Structure: The offering includes 3,870,500 common shares with accompanying common share warrants at $5.50 per unit, and 675,000 pre-funded warrants with accompanying warrants at $5.4999 per unit.
- Warrant Terms: Each common share warrant is immediately exercisable at a price of $7.50 per share and will expire on the earlier of 18 months from issuance or 30 days following the company's public announcement of its Phase 2 vitiligo topline data for EB06.
- Underwriter & Closing: The offering is managed by Guggenheim Securities and is expected to close on or about August 21, 2026. Underwriters have a 30-day option to purchase up to 681,825 additional shares and warrants.